When should an interim analysis be unblinded to the data monitoring committee?
Knottnerus
J André
JA
Department of General Practice, Care and Public Health Research Institute (Caphri), Faculty of Health, Medicine and Life Sciences, Maastricht University, 6220 MD Maastricht, The Netherlands. andre.knottnerus@hag.unimaas.nl
Spigt
Mark G
MG
D035843:Biomedical Research; D026661:Clinical Trials Data Monitoring Committees; D003627:Data Interpretation, Statistical; D030881:Disclosure; D006801:Humans; D012107:Research Design; D013997:Time Factors